Melinta Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Melinta Therapeutics sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Melinta Therapeutics: 31 sponsored US clinical trials, none currently recruiting.
Melinta Therapeutics sponsors 31 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 29 completed. 10 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cellulitis, with 2 trials.
Top-decile sponsor footprint
Melinta Therapeutics ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
31 total, page 1 of 1
Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
NCT05599295
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
NCT03873987
Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults
NCT03534622
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
NCT03159403
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
NCT02679573
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
NCT02605122
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
NCT02510599
Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects
NCT02505997
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
NCT02470702
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
NCT02340988
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
NCT02268279
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
NCT02166476
Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
NCT02245243
Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
NCT02210325
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT01984684
Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
NCT02134301
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
NCT02015637
Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents
NCT01966055
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
NCT01968733
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT01811732
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
NCT01784536
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
NCT01762839
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
NCT01756339
Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea
NCT01591447
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
NCT01283581
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
NCT01252732
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
NCT01252719
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
NCT01168713
Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
NCT00719810
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
NCT00646958
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
NCT00640926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 9 |
| Phase 3 | 10 |
How the Melinta Therapeutics early-phase archive is shaped
31 indexed studies, none listed as recruiting (0% open); 29 completed (94%).
Phase mix: 10 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Cellulitis (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Melinta Therapeutics: archived-pipeline peers nationwide
Peers matched on 31 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Melinta Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 archived trials
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Melinta Therapeutics page
31 registered trials is a research-attention snapshot, not an endorsement of Melinta Therapeutics or any single study.
- None of Melinta Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cellulitis is the condition Melinta Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cellulitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Melinta Therapeutics pipeline card: 31 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.